economic repercussions, including job losses, mental health challenges, and disruptions to education. Balancing public health priorities with economic and social impacts became a key challenge, prompting adaptations such as phased reopenings, targeted lockdowns, and increasedreliance on digital infrastructure for work, education, and communication[7].

B. Re-emerging Viruses

(i) **Dengue and Zika**

Dengue and Zika viruses, both transmitted primarily by *Aedesaegypti* mosquitoes, are significant public health threats in tropical and subtropical regions. Dengue virus causes dengue fever, characterized by high fever, severe headaches, joint pain, and in severe cases, life-threatening complications like dengue hemorrhagic fever and dengue shock syndrome.

Zika virus, while often causing mild symptoms such as fever, rash, and conjunctivitis, is particularly dangerous for pregnant women as it can lead to congenital Zika syndrome, causing microcephaly and other severe birth defects in infants.

Both viruses highlight the challenges posed by vector-borne diseases, including the role of climate change in expanding mosquito habitats and the lack of specific antiviral treatments. Preventative measures, such as mosquito control programs, public awareness campaigns, and ongoing research into vaccines and treatments, are critical in reducing the global burden of these disease[8].

(ii) **Measles**

Measles is a highly contagious viral disease caused by the measles virus, a member of the *Paramyxoviridae* family. It spreads through respiratory droplets and can infect up to 90% of unvaccinated individuals exposed to an infected person. Symptoms typically begin with high fever, cough, runny nose, and conjunctivitis, followed by a characteristic red, blotchy rash. While often self-limiting, measles can lead to severe complications, including pneumonia, encephalitis, and death, particularly in young children and immunocompromised individuals. Despite the availability of a safe and highly effective vaccine, measles outbreaks persist in regions with low vaccination coverage, often exacerbated by misinformation about vaccine safety. Measles remains a stark reminder of the importance of vaccination programs and global efforts to achieve herd immunity to prevent its resurgence[9].

(iii) **Hendra Virus**

Hendra virus is a rare but serious virus that primarily affects horses and can be transmitted to humans, often with fatal consequences. It was first identified in 1994 in Hendra, Queensland, Australia, when several horses fell ill and died, with a small number of human cases following. The virus is part of the Henipavirus genus and is carried by flying foxes (fruit bats), which are believed to be the natural reservoir. Human infections are typically associated with close contact with infected horses, leading to symptoms such as fever, headaches, respiratory distress, and encephalitis. While Hendra virus infections in humans are rare, the severity and potential for fatal outcomes make it a major public health concern, particularly in regions where horses and bats are in close proximity. Research into vaccines and treatments for Hendra virus has intensified in response to its zoonotic potential and the risk it poses to both animal and human populations[10].

C. High-Fatality Viruses

(i) ***Ebola and Marburg***

Ebola and Marburg viruses, both members of the *Filoviridae* family, are highly lethal pathogens responsible for severe hemorrhagic fevers in humans and primates. Transmitted through direct contact with infected bodily fluids, contaminated surfaces, or animals, these viruses cause rapid disease progression marked by fever, muscle pain, vomiting, diarrhea, and in severe cases, internal and external bleeding. Ebola, first identified in 1976, has caused numerous outbreaks, with the 2014–2016 West Africa epidemic being the largest, while Marburg virus, first detected in 1967, has resulted in smaller but equally deadly outbreaks. Both viruses have high mortality rates, ranging from 25% to 90%, depending on the outbreak and medical response. Effective prevention hinges on early detection, strict infection control measures, community education, and, in the case of Ebola, the use of newly developed vaccines. Ongoing research is critical to improving treatments and containment strategies for these devastating diseases[11].

(ii) ***Nipah Virus***

With a high fatality rate and potential for person-to-person transmission, Nipah remains

a critical area of concern with 40-75% mortality rate.Nipah virus (NiV), a zoonotic pathogen belonging to the *Paramyxoviridae* family, is an emerging global health threat due to its high mortality rate and potential for human-to-human transmission. First identified during an outbreak in Malaysia in 1998, the virus is primarily transmitted to humans through direct contact with infected animals, such as fruit bats (natural reservoirs) or pigs, as well as contaminated food or fluids. Nipah infection can cause a range of symptoms, from mild respiratory illness to severe encephalitis, leading to coma or death in severe cases. With no specific antiviral treatments or vaccines currently available, management relies on supportive care and strict infection control measures. Frequent outbreaks in South and Southeast Asia underscore the need for robust surveillance, early detection, and research into preventive measures, as well as public awareness to mitigate the risk of spillover events[12].

2. Social and Economic Impacts

Viruses significantly influence societal and economic structures, often creating long-term challenges.Viral outbreaks have profound social and economic impacts, often disrupting daily life and global stability. On a social level, they can cause widespread fear, stigma, and isolation as communities implement quarantines, social distancing, and other public health measures to control the spread. Education systems are often disrupted as schools close, and healthcare systems become overwhelmed, leading to delayed or inaccessible care for other medical needs. Economically, viral outbreaks can result in massive job losses, reduced productivity, and financial instability as businesses shut down and supply chains are interrupted. Tourism, trade, and industries reliant on global connectivity often suffer significant losses. Governments and households face increased financial burdens due to healthcare costs and recovery efforts. Long-term consequences may include increased poverty, inequality, and a slower pace of economic growth, making it essential to invest in preparedness and resilience to reduce the societal and economic toll of future outbreaks[13,14].

A. Health Disparities

The burden of viral diseases disproportionately affects low-income and marginalized communities, exposing global inequities in healthcare access and resource distribution. Health disparities caused by viruses highlight the unequal impact infectious diseases have on different populations, often exacerbating existing health inequalities. Marginalized groups, including racial and ethnic minorities, low-income communities, and individuals with pre-existing health conditions, are particularly vulnerable to viral infections. Factors such as limited access to healthcare, lack of vaccination, crowded living conditions, and systemic inequities in healthcare systems contribute to these disparities.For example, during the COVID-19 pandemic, Black and Latino communities experienced higher infection rates and more severe outcomes, including hospitalization and death, compared to white populations. Addressing these disparities requires improving healthcare access, increasing education on prevention, and ensuring that resources are equitably distributed to those most at risk[15,16].

B. Economic Costs

Viral outbreaks disrupt industries, from healthcare and education to travel and trade. For instance, COVID-19 led to global economic losses estimated in the trillions of dollars. Virus 5 outbreaks can lead to significant economic losses, disrupting industries, global supply chains, and everyday economic activities. As businesses close or reduce operations due to health concerns or government-imposed restrictions, industries such as travel, hospitality, and retail are particularly hard-hit. Job losses and reduced wages lead to lower consumer spending, which further slows down economic growth. The broader economy may face recessions, with stock markets experiencing volatility and businesses scaling back on investments. In addition, healthcare costs surge as resources are redirected toward managing the outbreak. Governments often need to implement emergency relief packages, which strain public finances. The long-term impact can be felt for years, as economies struggle to recover and rebuild from the effects of a viral crisis[17,18].

C. Mental Health

Prolonged pandemics, fear of infection, and economic uncertainty contribute to widespread mental health issues, including anxiety, depression, and post-traumatic stress. The fear of contracting the virus, along with isolation due to lockdowns and social distancing measures, can lead to increased feelings of loneliness and depression. For many, the constant media coverage and information overload contribute to heightened

anxiety. Those already dealing with mental health conditions may experience exacerbated symptoms, while others may develop new mental health struggles, including post-traumatic stress disorder (PTSD), insomnia, and panic attacks. The economic hardships and loss of jobs further add to the psychological burden, leading to a sense of hopelessness or despair. Additionally, the loss of loved ones or uncertainty about the future can deepen emotional distress. Addressing mental health during a pandemic requires both immediate psychological support and long-term strategies to help individuals cope with the ongoing challenges[19].

3. Advances in Science and Medicine

Despite their destructive potential, viruses have driven significant scientific and medical advancements. The rapid progression of science and medicine has played a pivotal role in combating viral threats. Key advancements include:

A. Vaccine Technology

The rapid development of mRNA vaccines during the COVID-19 pandemic represents a ground-breaking shift in vaccine technology, paving the way for vaccines against other viruses. The outbreak of viruses like COVID-19 has accelerated advancements in vaccine technologies, leading to innovative approaches in vaccine development. One major breakthrough has been the development of mRNA vaccines, which allow for faster production and greater flexibility in response to emerging viruses. These vaccines, such as those developed by Pfizer-BioNTech and Moderna, work by instructing cells to produce a protein that triggers an immune response. Viral vector vaccines, another advancement, use harmless viruses to deliver genetic material that prompts immunity, as seen in the AstraZeneca and Johnson & Johnson vaccines. The pandemic has also spurred improvements in vaccine distribution and storage technologies, making vaccines more accessible globally and enhancing their effectiveness in diverse environments[20, 21].

B. Antiviral Therapies

The outbreak of viral pandemics has led to significant advances in antiviral therapies, expanding treatment options for a range of infections. Researchers have developed novel antiviral drugs that target specific stages of the viral lifecycle, such as protease inhibitors and polymerase inhibitors, which have proven effective against viruses like HIV, Hepatitis C, and SARS-CoV-2. The rapid development of antiviral treatments for COVID-19, such as Remdesivir and Paxlovid, has demonstrated the potential for swift therapeutic innovation in response to emerging threats. Additionally, advances in monoclonal antibody therapies have provided effective tools for treating and preventing viral infections by mimicking the immune response. The global focus on antiviral research has also led to improved drug delivery systems and combination therapies that enhance the effectiveness of treatments and reduce the development of resistance[22].

C. Virology and Genomics

Advances in genomics have enabled real-time tracking of viral mutations, informing public health responses and guiding vaccine updates. The outbreak of viral infections has spurred significant advances in virology and genomics, enhancing our ability to understand and combat viruses. The rapid sequencing of viral genomes, as seen with the SARS-CoV-2 virus, has revolutionized how quickly we can identify and track emerging pathogens. Advances in next-generation sequencing technologies have enabled scientists to map the genetic makeup of viruses with unprecedented speed and accuracy, improving diagnostic capabilities. These advancements have also paved the way for the development of targeted therapies and vaccines, by providing deeper insights into how viruses mutate and interact with host cells. Furthermore, genomic surveillance networks have become vital tools in tracking viral spread, identifying new variants, and informing public health responses globally[23, 24].

D. Virus-Based Innovations

Viruses are used as tools in gene therapy, oncolyticvirotherapy (targeting cancer cells), and vaccine development for non-viral diseases.

(i) **Genomic Technologies**

High-throughput sequencing has revolutionized our ability to detect and characterize novel pathogens swiftly. Technologies like CRISPR have enabled precision diagnostics and therapeutic interventions, allowing for targeted treatments of viral infections[25].

(ii) **mRNA Vaccine Platforms**

The development of mRNA vaccines for COVID-19 demonstrated unprecedented speed and effectiveness, paving the way for similar approaches against other pathogens. This platform allows for rapid adjustments

to vaccines in response to viral mutations, addressing evolving strains[26].

(iii) **Artificial Intelligence (AI) in Disease Modelling**

AI tools are now widely used for predictive modelling, helping to identify outbreak patterns and optimize intervention strategies. Machine learning algorithms facilitate the analysis of vast datasets, enabling the discovery of potential drug targets and the optimization of public health responses[27].

(iv) **Broad-Spectrum Antiviral Agents**

Research into drugs effective against multiple virus families is underway, potentially providing a first line of defense against novel pathogens.These antivirals target conserved viral mechanisms, reducing the time needed for drug development during outbreaks[28].

(v) **Nanotechnology in Drug Delivery**

Advances in nanotechnology have enabled precise delivery of antiviral agents, improving their efficacy and minimizing side effects. Nanoparticles are also being explored for use in diagnostics and vaccine delivery[29].

(vi) **Improved Surveillance Tools**

Portable diagnostic kits, wearable health monitors, and mobile labs have enhanced real-time surveillance capabilities. Integration with digital health platforms ensures faster reporting and response to emerging threats[30].

(vii) **Synthetic Biology**

Synthetic biology enables the creation of novel vaccines and therapeutic compounds by engineering microorganisms or biomolecules. This field also aids in understanding virus-host interactions, improving our ability to design effective interventions[31].

(viii) **Telemedicine and Remote Monitoring**

Digital health technologies have expanded access to healthcare, particularly during outbreaks when physical contact must be minimized.Remote monitoring of patients supports early intervention and reduces strain on healthcare facilities[32].

(ix) **Public-Private Partnerships in Research**

Collaborative efforts between governments, academia, and industry have accelerated the translation of scientific discoveries into practical solutions. Initiatives like CEPI (Coalition for Epidemic Preparedness Innovations) have played a crucial role in funding vaccine development[33].

4. Societal Behaviour and Misinformation

During a virus outbreak, societal behaviour and misinformation can significantly influence the trajectory of the crisis. Fear and uncertainty often amplify the spread of misinformation, leading to the circulation of false remedies, conspiracy theories, and exaggerated risks. This can undermine public health efforts, as individuals may disregard official guidelines, such as wearing masks or getting vaccinated, in favour of unproven alternatives. Panic buying and stigmatization of affected communities can further exacerbate social tensions and disrupt the equitable distribution of resources. Conversely, collective responsibility, trust in credible sources, and widespread adherence to preventive measures can mitigate the outbreak's impact. Clear communication and combating misinformation are thus crucial in fostering informed societal behaviour and curbing the spread of both the virus and harmful falsehoods[34].

A. Vaccine Hesitancy

Misinformation has fuelled resistance to vaccines, leading to the resurgence of preventable diseases like measles and polio in certain regions. Vaccine hesitancy fuelled by misinformation poses a significant threat to public health, especially during disease outbreaks. Misinformation spreads rapidly through social media and other platforms, often promoting unfounded fears about vaccine safety, effectiveness, and necessity. Myths about vaccines causing severe side effects, altering DNA, or being part of conspiratorial agendas can erode public trust in immunization programs. This hesitation delays herd immunity, prolongs the outbreak, and increases the vulnerability of high-risk populations. Addressing vaccine hesitancy requires transparent communication, community engagement, and the active debunking of false claims. Equipping people with accurate, evidence-based information helps build confidence in vaccines and underscores their critical role in saving lives and controlling infectious diseases[35].

B. Hygiene and Public Health Awareness

The COVID-19 pandemic emphasized the importance of basic hygiene practices, such as handwashing and mask-wearing, in preventing viral transmission. Hygiene and public health awareness play a pivotal role in controlling the spread of viruses during outbreaks. Simple practices such as regular handwashing, using sanitizers, covering coughs, and wearing masks can significantly reduce transmission rates. Public

health campaigns emphasizing these behaviors, along with guidelines on physical distancing and symptom monitoring, help individuals understand their responsibility in protecting themselves and others. Raising awareness about early detection, isolation protocols, and the importance of seeking medical attention fosters a proactive approach to containment. Effective communication tailored to diverse communities ensures widespread compliance, creating a collective shield against the virus and reducing the strain on healthcare systems[36].

C. Global Collaboration

Viral outbreaks have underscored the importance of international collaboration in disease surveillance, research, and response. Global collaboration is essential during a virus outbreak, as no nation can effectively combat a pandemic in isolation. Coordinated efforts among governments, international organizations, and healthcare institutions enable the sharing of critical resources, such as vaccines, medicines, and personal protective equipment, ensuring that even resource-limited regions have access to essential tools. Collaborative research accelerates the development of treatments and vaccines by pooling expertise, data, and funding across borders. Organizations like the World Health Organization (WHO) play a central role in disseminating accurate information and standardizing responses to the crisis. Moreover, global solidarity fosters the exchange of best practices and lessons learned, empowering nations to implement effective containment strategies. By working together, the international community can reduce disparities, curb the spread of the virus, and mitigate its far-reaching social and economic impacts[37].

5. Factors Driving the Emergence of New Viruses

A. Globalization and Urbanization

Globalization and urbanization are key factors driving the emergence and spread of new viruses. Increased global connectivity through travel and trade accelerates the cross-border movement of pathogens, turning localized outbreaks into global threats within days. Urbanization amplifies this risk by concentrating large populations in densely populated areas, where close contact and inadequate sanitation provide ideal conditions for viral transmission. Rapid deforestation and habitat destruction often driven by urban expansion bring humans into closer contact with wildlife, increasing the chances of zoonotic diseases spilling over. Markets selling live animals, which are common in some urban areas, further amplify the risk of novel pathogens jumping species. Addressing these challenges requires integrated approaches, including monitoring high-risk environments, improving urban infrastructure, and enhancing global surveillance systems to mitigate the emergence of new viruses[38].

B. Climate Change

Climate change is a significant factor driving the emergence of new viruses by altering ecosystems and disrupting the natural balance between humans, animals, and pathogens. Rising global temperatures and shifting weather patterns affect the habitats and behaviors of wildlife, leading to increased interactions between species that might not otherwise come into contact. This heightened interspecies interaction creates opportunities for zoonotic diseases—those that jump from animals to humans—to emerge. Additionally, climate change facilitates the expansion of disease-carrying vectors like mosquitoes and ticks into new regions, spreading viruses such as dengue, Zika, and Lyme disease to previously unaffected populations. Melting permafrost and ice caps may even release ancient pathogens that have been dormant for centuries. Addressing the link between climate change and viral emergence requires global efforts to reduce greenhouse gas emissions, conserve biodiversity, and strengthen public health infrastructure to monitor and respond to new threats[39].

C. Deforestation and Habitat Disruption

Deforestation and habitat disruption are critical factors driving the emergence of new viruses by increasing human exposure to wildlife and their pathogens. When forests are cleared for agriculture, urban development, or logging, the natural habitats of animals are destroyed, forcing them to migrate closer to human populations. This heightened interaction facilitates the spillover of zoonotic diseases viruses that jump from animals to humans such as Ebola, Nipah, and coronaviruses. Fragmented ecosystems also weaken natural biodiversity, which often acts as a buffer against disease transmission, allowing certain host species to thrive and spread pathogens more easily. Additionally, activities like hunting, wildlife trade, and the establishment of livestock farms in deforested areas further amplify the risk of viral outbreaks. Addressing these challenges requires sustainable land-use practices, habitat conservation, and improved monitoring of wildlife-human interactions to minimize the risk of future pandemics[40].

D. Antimicrobial Resistance and Health System Gaps

Antimicrobial resistance (AMR) and gaps in health systems are significant factors driving the emergence and spread of new viruses. Overuse and misuse of antibiotics and antivirals in humans, animals, and agriculture contribute to the development of resistant pathogens, which can complicate the treatment of viral co-infections and weaken overall public health defences. Health system gaps, such as inadequate disease surveillance, limited access to healthcare, and underfunded public health infrastructure, further exacerbate the problem by delaying the detection and response to emerging threats. In regions with weak health systems, outbreaks can spread unchecked, increasing the likelihood of viruses mutating and becoming more dangerous. Strengthening health systems globally, promoting responsible antimicrobial use, and investing in research and development are critical steps to address these interconnected challenges and reduce the risk of future pandemics[41, 42].

6. Challenges in Managing Emerging Viral Threats

A. Surveillance and Early Detection

Current surveillance systems are often fragmented and under-resourced, particularly in low- and middle-income countries. Delayed detection hampers timely responses to contain outbreaks[43].

B. Vaccine and Therapeutic Development

The development of vaccines and antiviral therapies is a time-intensive and costly process. Viruses with high mutation rates, such as influenza and SARS-CoV-2, complicate vaccine design and efficacy[44].

C. Misinformation and Public Perception

The spread of misinformation can undermine public trust in health interventions and hinder effective outbreak management. Social media platforms have been a double-edged sword, providing both valuable information and avenues for misinformation[45].

D. Global Inequities in Health Resources

Disparities in healthcare access and resources exacerbate the impact of viral outbreaks in vulnerable populations. Ensuring equitable distribution of vaccines and treatments remains a significant challenge[46].

7. Preparing for Future Viral Threats

Viruses will continue to emerge and evolve, necessitating proactive measures to mitigate their impact on society. The increasing frequency of viral outbreaks demands a proactive approach to future threats. Key measures include:

A. Strengthening Health Systems

Strengthening health systems is essential for preparing for future viral threats and mitigating the impact of pandemics. Robust health systems must prioritize early detection and rapid response by investing in advanced disease surveillance technologies, laboratory capacity, and data-sharing frameworks. Expanding healthcare infrastructure, including sufficient hospital beds, medical supplies, and well-trained personnel, ensures readiness for surges in demand during outbreaks. Strengthening primary healthcare and promoting universal health coverage enable equitable access to preventive measures, vaccines, and treatments, reducing the spread of infections in vulnerable populations. Public health campaigns that foster trust and community engagement play a vital role in ensuring adherence to safety protocols. Global collaboration, combined with sustained investment in research and innovation, creates a resilient foundation for identifying, managing, and containing emerging viral threats, protecting lives, and minimizing socio-economic disruptions[47].

B. Enhancing Surveillance

Enhancing surveillance systems is a cornerstone of preparing for future viral threats, enabling early detection, monitoring, and response to potential outbreaks. Advanced surveillance involves integrating modern technologies, such as artificial intelligence, genomic sequencing, and real-time data analytics, to track disease patterns and identify unusual activity in human, animal, and environmental health. Strengthening global networks like the One Health approach ensures a comprehensive understanding of zoonotic disease risks and facilitates the sharing of critical information across countries. Community-level surveillance and partnerships with local healthcare providers improve the detection of emerging threats in remote or underserved areas. Regular training for health workers and robust reporting mechanisms further enhance the effectiveness of these systems. Proactive surveillance not only helps contain outbreaks before they escalate but also informs vaccine development, public health policies, and global preparedness strategies, creating a stronger defense against future viral threats[48].

C. Promoting Education

Promoting education is a vital strategy for preparing for future viral threats, as informed communities are better equipped to prevent and respond to outbreaks. Public health education campaigns that focus on hygiene practices, vaccination, and the importance of early symptom recognition can significantly reduce transmission rates and improve compliance with preventive measures. By integrating virus-related topics into school curricula and public health training, we can foster a more informed population that understands the importance of staying vigilant during potential outbreaks. Media platforms, healthcare workers, and community leaders also play key roles in disseminating accurate information, combating misinformation, and ensuring that individuals understand how their actions contribute to public health. Empowering people with the knowledge to make informed decisions about health, hygiene, and safety helps create resilient communities capable of minimizing the impact of future viral threats[49].

(i) **Global Coordination**

Strengthening international partnerships to share data, expertise, and resources is crucial for managing cross-border outbreaks. Organizations like the WHO should be supported to facilitate coordinated global responses[50].

(ii) **Investing in Research and Innovation**

Accelerating research into emerging viruses and potential treatments can improve preparedness. Innovative technologies, including artificial intelligence, can enhance predictive modelling and outbreak simulations[51].

(iii) **Expanding Vaccine Equity**

Ensuring equitable access to vaccines and treatments for all populations will mitigate the disproportionate impact on vulnerable groups. Establishing regional manufacturing hubs can reduce reliance on global supply chains[52].

(iv) **Strengthening Health Education**

Raising public awareness about viral threats and preventive measures fosters community resilience.Combatting misinformation through transparent and credible communication is essential[53].

(v) **Enhancing Rapid Response Capabilities**

Developing rapid deployment teams and stockpiling essential medical supplies can minimize response times during outbreaks. Simulation exercises and training programs can ensure readiness for diverse scenarios[54].

(vi) **Integrating One Health into Policy**

Addressing the interconnectedness of human, animal, and environmental health is crucial for mitigating zoonotic risks.Policies should focus on sustainable land use, wildlife conservation, and vector control[55].

(vii) **Strengthening Localized Healthcare Infrastructure**

Building capacity at the community level ensures early detection and response capabilities.Equipping regional health centers with advanced diagnostic tools and personnel prepares them for outbreaks in remote or underserved areas[56].

(viii) **Expanding Global Funding Mechanisms**

Establishing emergency funds dedicated to outbreak preparedness and response enables rapid action. International financial institutions can support under-resourced nations in building their health capacities[57].

(ix) **Advancing Diagnostic and Monitoring Technologies**

Deploying portable diagnostic tools and real-time monitoring systems can accelerate outbreak identification. Integration of AI and machine learning can improve the accuracy and efficiency of predictive outbreak models [58, 59].

CONCLUSION

The threat of emerging viruses in the modern world is a complex and multifaceted challenge that requires coordinated global action. By addressing the underlying drivers of disease emergence and investing in robust surveillance, research, and health systems, the global community can better prepare for and mitigate the impact of future outbreaks. The lessons learned from recent pandemics should serve as a catalyst for sustained efforts to protect public health and ensure a safer, more resilient world.Viruses are an ever-present force in society, capable of causing significant harm but also driving scientific and technological advancements. By addressing the factors that exacerbate viral threats and leveraging the lessons learned from past outbreaks, society can better navigate the challenges posed by viruses while reaping the benefits of the innovations they inspire.

REFERENCES

1. Berliner A.J., Mochizuki T., Stedman K.M. Astrovirology: Viruses at Large in the Universe. Astrobiology. 2018; 18(2):207-23.
2. Morse S.S. The public health threat of emerging viral disease. The Journal of nutrition. 1997; 127(5):951S-7S.
3. Morens D.M., Fauci A.S. Emerging infectious diseases: threats to human health and global stability. PLoS pathogens. 2013; 9(7):e1003467.
4. Hutchinson EC. Influenza virus. Trends in microbiology. 2018; 26(9):809-10.
5. German Advisory Committee Blood SAoPTbB. Human immunodeficiency virus (HIV). Transfusion medicine and hemotherapy. 2016; 43(3):203-22.
6. Ciotti M., Ciccozzi M., Terrinoni A., Jiang W-C, Wang C.B., Bernardini S. The COVID-19 pandemic. Critical reviews in clinical laboratory sciences. 2020; 57(6):365-88.
7. Askitas N., Tatsiramos K., Verheyden B. Lockdown strategies, mobility patterns and covid-19. arXiv preprint arXiv:200600531. 2020.
8. Elong Ngono A., Shresta S. Immune response to dengue and Zika. Annual review of immunology. 2018; 36(1):279-308.
9. Bellini W.J., Rota J.S., Rota P.A. Virology of measles virus. Journal of Infectious Diseases. 1994; 170 (Supplement_1):S15-S23.
10. Middleton D. Hendra virus. Veterinary Clinics: Equine Practice. 2014; 30(3):579-89.
11. Rougeron V., Feldmann H., Grard G., Becker S., Leroy E. Ebola and Marburg haemorrhagic fever. Journal of Clinical Virology. 2015;64:111-9.
12. Ang B.S., Lim T.C., Wang L. Nipah virus infection. Journal of clinical microbiology. 2018; 56(6):10.1128/jcm. 01875-17.
13. Yip P.S., Cheung Y., Chau P.H., Law Y. The impact of epidemic outbreak. Crisis. 2010.
14. Heymann D.L. Social, behavioural and environmental factors and their impact on infectious disease outbreaks. Journal of public health policy. 2005; 26:133-9.
15. Bambra C. Pandemic inequalities: emerging infectious diseases and health equity. International Journal for Equity in Health. 2022; 21(1):6.
16. Braveman P. Health disparities and health equity: concepts and measurement. Annual review of public health. 2006; 27(1):167-94.
17. Smith K.M., Machalaba C.C., Seifman R., Feferholtz Y., Karesh WB. Infectious disease and economics: The case for considering multi-sectoral impacts. One health. 2019; 7:100080.
18. Rasul I., editor The economics of viral outbreaks. AEA Papers and Proceedings; 2020: American Economic Association 2014 Broadway, Suite 305, Nashville, TN 37203.
19. Ricci-Cabello I., Meneses-Echavez J.F., Serrano-Ripoll M.J., Fraile-Navarro D, de Roque MAF, Moreno G.P., *et al*. Impact of viral epidemic outbreaks on mental health of healthcare workers: a rapid systematic review. MedRxiv. 2020:2020.04. 02.20048892.
20. Rauch S., Jasny E., Schmidt K.E., Petsch B. New vaccine technologies to combat outbreak situations. Frontiers in immunology. 2018;9:1963.
21. Graham B.S. Advances in antiviral vaccine development. Immunological reviews. 2013; 255(1):230-42.
22. Gonçalves B.C., Lopes Barbosa M.G., Silva Olak A.P., Belebecha Terezo N., Nishi L., Watanabe M.A., *et al*. Antiviral therapies: advances and perspectives. Fundamental & Clinical Pharmacology. 2021; 35(2):305-20.
23. Wohl S., Schaffner S.F., Sabeti PC. Genomic analysis of viral outbreaks. Annual review of virology. 2016; 3(1):173-95.
24. Hill V., Ruis C., Bajaj S., Pybus O.G., Kraemer MU. Progress and challenges in virus genomic epidemiology. Trends in Parasitology. 2021; 37(12):1038-49.
25. Ghorbani A., Hadifar S., Salari R., Izadpanah K., Burmistrz M., Afsharifar A., *et al*. A short overview of CRISPR-Cas technology and its application in viral disease control. Transgenic Research. 2021; 30:221-38.
26. Kumar A., Blum J., Le T.T., Havelange N., Magini D., Yoon I.K. The mRNA vaccine development landscape for infectious diseases. Nat Rev Drug Discov. 2022;21(5):333-4.
27. Sim S., Cho M. Convergence model of AI and IoT for virus disease control system. Personal and Ubiquitous Computing. 2023;27(3):1209-19.
28. Adalja A., Inglesby T. Broad-spectrum antiviral agents: a crucial pandemic tool. Expert review of Anti-infective Therapy. 2019;17(7):467-70.
29. Delshadi R., Bahrami A., McClements DJ, Moore MD, Williams L. Development of nanoparticle-delivery systems for antiviral agents: A review. Journal of Controlled Release. 2021;331:30-44.
30. Mukherjee S., Suleman S., Pilloton R., Narang J., Rani K. State of the art in smart portable, wearable, ingestible and implantable devices for health status monitoring and disease management. Sensors. 2022;22(11):4228.
31. Kitney R.I., Bell J., Philp J. Build a sustainable vaccines industry with synthetic biology. Trends in Biotechnology. 2021;39(9):866-74.
32. Field M.J., Grigsby J. Telemedicine and remote patient monitoring. Jama. 2002;288(4):423-5.

33. Brende B., Farrar J., Gashumba D., Moedas C., Mundel T., Shiozaki Y., *et al*. CEPI—a new global R&D organisation for epidemic preparedness and response. The Lancet. 2017; 389(10066):233-5.
34. AROUND E., ARE V. The biggest pandemic risk? Viral misinformation. 2018.
35. Dubé E., Laberge C., Guay M., Bramadat P., Roy R., Bettinger J.A. Vaccine hesitancy: an overview. Human vaccines & immunotherapeutics. 2013; 9(8):1763-73.
36. Chowdhury T., Nandi S. Food safety, hygiene, and awareness during combating of COVID-19. Environmental and health management of novel coronavirus disease (COVID-19): Elsevier; 2021. p. 305-24.
37. Kinsella C.M., Santos P.D., Postigo-Hidalgo I., Folgueiras-Gonzalez A., Passchier T.C., Szillat K.P., *et al*. Preparedness needs research: How fundamental science and international collaboration accelerated the response to COVID-19. PLoS pathogens. 2020; 16(10):e1008902.
38. Wu T., Perrings C., Kinzig A., Collins J.P., Minteer B.A., Daszak P. Economic growth, urbanization, globalization, and the risks of emerging infectious diseases in China: A review. Ambio. 2017; 46:18-29.
39. Gould E.A., Higgs S. Impact of climate change and other factors on emerging arbovirus diseases. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2009; 103(2):109-21.
40. do Amaral C.G., André E.P., Cilli E.M., da Costa V.G., Sanches PRS. Viral diseases and the environment relationship. Environmental Pollution. 2024:124845.
41. Ferri M., Ranucci E., Romagnoli P., Giaccone V. Antimicrobial resistance: A global emerging threat to public health systems. Critical reviews in food science and nutrition. 2017; 57(13):2857-76.
42. Baral P. Health systems and services during COVID-19: lessons and evidence from previous crises: a rapid scoping review to inform the United Nations research roadmap for the COVID-19 recovery. International Journal of Health Services. 2021; 51(4):474-93.
43. Shen Y., Liu Y., Krafft T., Wang Q. Progress and challenges in infectious disease surveillance and early warning. Medicine Plus. 2025:100071.
44. Kim K.S. Current challenges in the development of vaccines and drugs against emerging vector-borne diseases. Current medicinal chemistry. 2019; 26(16):2974-86.
45. Swire-Thompson B., Lazer D. Public health and online misinformation: challenges and recommendations. Annu Rev Public Health. 2020; 41(1):433-51.
46. Quinn S.C., Kumar S. Health inequalities and infectious disease epidemics: a challenge for global health security. Biosecurity and bioterrorism: biodefense strategy, practice, and science. 2014; 12(5):263-73.
47. da Costa Monteiro E., Pinto J. The Next Pandemic: Preparing for Future Global Health Threats. Medical Studies and Health Journal (SEHAT). 2024; 1(1):85-100.
48. Gupta S., Gupta T., Gupta N. Global respiratory virus surveillance: strengths, gaps, and way forward. International Journal of Infectious Diseases. 2022; 121:184-9.
49. Lopes H., McKay V. Adult learning and education as a tool to contain pandemics: The COVID-19 experience. International review of education. 2020; 66(4):575-602.
50. Bloom D.E., Cadarette D. Infectious disease threats in the twenty-first century: strengthening the global response. Frontiers in immunology. 2019; 10:549.
51. Durugbo C.M., Almahamid SM, Budalamah L.H., Al-Jayyousi O.R., BendiMerad B. Preparedness for innovation in times of crisis: Lessons from the initial COVID-19 pandemic response. International Journal of Innovation and Technology Management. 2022; 19(06):2140012.
52. Jean-Jacques M., Bauchner H. Vaccine distribution—equity left behind? Jama. 2021; 325(9):829-30.
53. SWARGIARY K. Health Education: Foundations, Strategies, and Innovations: EdTech Research Association, US; 2024.
54. Kuckertz A., Brändle L., Gaudig A., Hinderer S., Reyes CAM, Prochotta A, *et al*. Startups in times of crisis–A rapid response to the COVID-19 pandemic. Journal of Business Venturing Insights. 2020;13:e00169.
55. Erkyihun G.A., Alemayehu M.B. One Health approach for the control of zoonotic diseases. Zoonoses. 2022; 2(1):963.
56. Regmi K., Gilbert R., Thunhurst C. How can health systems be strengthened to control and prevent an Ebola outbreak? A narrative review. Infection Ecology & Epidemiology. 2015; 5(1):28877.
57. Pike J., Bogich T., Elwood S., Finnoff D.C., Daszak P. Economic optimization of a global strategy to address the pandemic threat. Proceedings of the National Academy of Sciences. 2014; 111(52):18519-23.
58. Kelly-Cirino C.D., Nkengasong J., Kettler H., Tongio I., Gay-Andrieu F., Escadafal C., *et al*. Importance of diagnostics in epidemic and pandemic preparedness. BMJ global health. 2019; 4(Suppl 2):e001179.
59. Milinovich G.J., Williams G.M., Clements A.C., Hu W. Internet-based surveillance systems for monitoring emerging infectious diseases. The Lancet infectious diseases. 2014; 14(2):160-8.